Tarsus Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Tarsus Pharmaceuticals, Inc. | TARS - NASDAQ |
$15.00-$17.00 | $16.00 | $16.20 | 5.5 million | 10/16/2020 |
| BofA Securities, Jefferies, Raymond James | ||||||
Co-Manager(s): LifeSci Capital, Ladenburg Thalmann | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-09-25 Terms Added 2020-10-09 | ||||||
Tarsus Pharmaceuticals, Inc. Quote & Chart - Click for current quote - TARS
IPO Boutique aggregates information on public companies and private companies, such as "TARS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Tarsus Pharmaceuticals, Inc. (adapted from Tarsus Pharmaceuticals, Inc. prospectus):
They are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "TARS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.